EMA Tightens Links With Academia To Boost Innovation And Regulatory Science
Executive Summary
A new framework for interactions between the EMA and the academic community is expected to foster innovation in new drugs and evaluation methodologies, by keeping the agency in touch with cutting-edge research and giving academics the chance to benefit more from the expertise in the EU regulatory network.
You may also be interested in...
New EU Action Plan To Boost Innovation By Smaller Firms
A new action plan from the European Medicines Agency is intended to promote innovation in SMEs by raising awareness of the regulatory tools and support available from the agency, offering more training and education, and promoting collaboration among SMEs, academia, and other stakeholders.
Pharma Firms Spend ‘Billions’ On Failing: More Collaboration Needed On Innovation
Speakers at a DIA EuroMeeting session on the challenges and opportunities facing regulators in the years to come discussed several options including more proactive engagement by regulators, more sharing by drug sponsors, and being innovative across the whole of the regulatory landscape.
Tech Transfer Roundup: Ohio State Turns To Industry Exec To Optimize Assets Before A Deal
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.